Jaime Sanz

Jaime Sanz

Auto-generated profile, based on publicly available information

Jaime Sanz

Departament de Medicina Universitat de Valencia, Hematology Department, Hospital Universitari i Politècnic La Fe, De Valencia, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
ASAlexandros Spyridonidis
Alexandros Spyridonidis
MLMyriam Labopin
Myriam Labopin
BSBipin N. Savani
Bipin N. Savani
RNRiitta Niittyvuopio
Riitta Niittyvuopio
DBDidier Blaise
Didier Blaise
MMMohamad Mohty
Mohamad Mohty

1 January 2008 in Haematologica
Verified
Journal Article
Closed access
PDF file
PMP. Montesinos
P. Montesinos
ILI. Lorenzo
I. Lorenzo
GMG. Martin
G. Martin
JSJ. Sanz
J. Sanz
MPM. L. Perez-Sirvent
M. L. Perez-Sirvent
Miguel SanzMiguel Sanz
Miguel Sanz
Background Despite the prophylactic use of allopurinol, tumor lysis syndrome (TLS)-related morbidity and mortality still occur in a number of patients with acute myeloid leukemia (AML). The aim of this study was: (i) to analyze the incidence and outcome of TLS in a large series of patients with AML receiving hyperhydration and allopurinol, (ii) to identify risk factors for TLS, and (iii) to develop a prognostic scoring system for estimating individual risk of TLS. Design and Methods The study included 772 adult patients with AML receiving induction chemotherapy between 1980 and 2002. TLS was divided into laboratory TLS (LTLS) or clinical TLS (CTLS). The population study was randomly divided into training and test subsets, so that a prognostic model for CTLS was developed in one set and validated in the other. Results Overall, 130 patients (17%) developed TLS (5% CTLS and 12% LTLS). Unlike LTLS, CTLS was associated with a higher rate of death from induction therapy. Multivariate analysis showed that pretreatment serum lactate dehydrogenase (LDH) levels above laboratory normal values, creatinine >1.4 mg/dL, uric acid >7.5 mg/dL and white blood cell (WBC) counts >25 × 109/L were independent risk factors for CTLS and LTLS. The scoring system, based on pretreatment WBC counts, and uric acid and LDH serum levels, had excellent discrimination and was accurate for predicting CTLS and LTLS. Conclusions TLS is frequently observed in AML patients during induction therapy. Only the development of CTLS had an impact on higher mortality rate from induction therapy. The scoring system derived from this study can be used to obtain an accurate estimate of the individual risk of TLS, allowing for risk-adapted prophylaxis against this complication.

17 April 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
ARA Ruggeri
A Ruggeri
MLM Labopin
M Labopin
GSG Sanz
G Sanz
SPS Piemontese
S Piemontese
WAW Arcese
W Arcese
MMM Mohty
M Mohty

10 January 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CRCelso A. Rodrigues
Celso A. Rodrigues
Guillermo F SanzGuillermo F Sanz
Guillermo F Sanz
CBClaudio G. Brunstein
Claudio G. Brunstein
JSJaime Sanz
Jaime Sanz
JWJohn E. Wagner
John E. Wagner
VRVanderson Rocha
Vanderson Rocha
Purpose: To determine risk factors of umbilical cord blood transplantation (UCBT) for patients with lymphoid malignancies. Patients and Methods: We evaluated 104 adult patients (median age, 41 years) who underwent unrelated donor UCBT for lymphoid malignancies. UCB grafts were two-antigen human leukocyte antigen–mismatched in 68%, and were composed of one (n = 78) or two (n = 26) units. Diagnoses were non-Hodgkin's lymphoma (NHL, n = 61), Hodgkin's lymphoma (HL, n = 29), and chronic lymphocytic leukemia (CLL, n = 14), with 87% having advanced disease and 60% having experienced failure with a prior autologous transplant. Sixty-four percent of patients received a reduced-intensity conditioning regimen and 46% low-dose total-body irradiation (TBI). Median follow-up was 18 months. Results: Cumulative incidence of neutrophil engraftment was 84% by day 60, with greater engraftment in recipients of higher CD34+ kg/cell dose (P = .0004). CI of non–relapse-related mortality (NRM) was 28% at 1 year, with a lower risk in patients treated with low-dose total-body irradiation (TBI; P = .03). Cumulative incidence of relapse or progression was 31% at 1 year, with a lower risk in recipients of double-unit UCBT (P = .03). The probability of progression-free survival (PFS) was 40% at 1 year, with improved survival in those with chemosensitive disease (49% v 34%; P = .03), who received conditioning regimens containing low-dose TBI (60% v 23%; P = .001), and higher nucleated cell dose (49% v 21%; P = .009). Conclusion: UCBT is a viable treatment for adults with advanced lymphoid malignancies. Chemosensitive disease, use of low-dose TBI, and higher cell dose were factors associated with significantly better outcome.

2 April 2020 in Haematologica
Verified
Journal Article
Open access
PDF file
Ali BazarbachiAli Bazarbachi
Ali Bazarbachi
GBGesine Bug
Gesine Bug
FBFrederic Baron
Frederic Baron
EBEolia Brissot
Eolia Brissot
FCFabio Ciceri
Fabio Ciceri
MMMohamad Mohty
Mohamad Mohty
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute myeloid leukemia . Because of the poor prognosis associated with FMS-like tyrosine kinase 3 internal tandem duplication mutated Acute myeloid leukemia, allogeneic-hematopoietic stem-cell transplantation was commonly performed in first complete remission. Remarkable progress has been made in frontline treatments with the incorporation of FLT3 inhibitors and the development of highly sensitive minimal/measurable residual disease assays. Similarly, recent progress in allogeneic-hematopoietic stem-cell transplantation includes improvement of transplant techniques, the use of haplo-identical donors in patients lacking an HLA matched donor, and the introduction of FLT3 inhibitors as posttransplant maintenance therapy. Nevertheless, current transplant strategies vary between centers and differ in terms of transplant indications based on the internal tandem duplication allelic ratio and concomitant nucleophosmin-1 mutation, as well as in terms of post-transplant maintenance/consolidation. This review generated by international leukemia or transplant experts, mostly from the European Society for Blood and Marrow Transplantation, attempts to develop a position statement on best approaches for allogeneic-hematopoietic stem-cell transplantation for acute myeloid leukemia with FMS-like tyrosine kinase internal tandem duplication including indications and modalities of allogeneic-hematopoietic stem-cell transplantation and on potential optimization of post-transplant maintenance with FMS-like tyrosine kinase inhibitors.

13 February 2012 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
JSJ Sanz
J Sanz
JBJuan Carlos Hernández Boluda
Juan Carlos Hernández Boluda
CMC Martín
C Martín
MGM González
M González
CFC Ferrá
C Ferrá
O(On Behalf Of Grupo Español de Trasplante Hematopoyético Y Terapia Celular (Geth)
On Behalf Of Grupo Español de Trasplante Hematopoyético Y Terapia Celular (Geth)
Attempts to optimize outcomes in cord blood transplantation (CBT) by using new conditioning regimens and standardization of cord blood unit selection are warranted. In all, 88 patients (18 children and 70 adults) with hematological malignancy from nine Spanish institutions underwent a single-unit CBT after an i.v. BU-based myeloablative conditioning regimen. All evaluable patients except one engrafted. The overall cumulative incidence (CI) of myeloid engraftment was 94% at a median time of 19 days. In multivariate analysis, nonadvanced disease stage was the only factor with a favorable impact on myeloid engraftment. The CI of acute GVHD grades II–IV and chronic extensive GVHD were 24% each. The CI of nonrelapse mortality at 100 days, 180 days and 5 years was 14, 23 and 44%, respectively. The 5-year CI of relapse was 18%, whereas disease-free survival (DFS) was 46%, 39% and 11% for patients transplanted in early, intermediate and advanced stages of the disease, respectively. Our study shows high rates of engraftment with fast neutrophil recovery in patients undergoing single-unit CBT using a BU-based conditioning regimen. Long-term DFS can be achieved in a substantial number of patients with high-risk hematological malignancies, particularly when transplanted in an early stage of the disease.